Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan.
Department of Internal Medicine, Yuri Kumiai General Hospital, Akita, Japan.
Clin Exp Nephrol. 2022 Aug;26(8):760-769. doi: 10.1007/s10157-022-02217-w. Epub 2022 Apr 8.
We determined the usefulness and prognostic ability of the renal risk score (RRS), proposed in Europe, for Japanese patients with antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (AAGN) and high myeloperoxidase (MPO)-ANCA positivity; these aspects remain to be verified.
This retrospective study was conducted on 86 Japanese patients with new, biopsy-confirmed AAGN. We calculated the RRS and analyzed the relationship between this classification, and clinicopathological features and prognosis. We also compared the predictive values between RRS for endpoints including renal death and conventional prognostic tools for patients with AAGN.
There were 33, 37, and 16 patients in the low-, medium-, and high-risk groups, respectively. All patients were MPO-ANCA positive. The median follow-up period was 33 months; 16 (18.6%) patients progressed to end-stage renal disease (ESRD). In the high-risk group, 9/16 (56.3%) patients progressed to ESRD, and renal prognosis was significantly poorer than that in other groups (low-risk group, P < 0.001; medium-risk group, P = 0.004). In Cox multivariate regression analysis, RRS was an independent, poor renal prognostic factor (hazard ratio 5.22; 95% confidence interval 2.20-12.40; P < 0.001). The receiver-operating characteristic curves of the RRS for each endpoint were comparable with those of the 2010 histological classification and those of the severity classification of Japanese rapidly progressive glomerulonephritis.
This is the first study to report the usefulness of the RRS for predicting renal outcomes among Japanese patients with AAGN. Our predictive value of the RRS was comparable with that of conventional prognostic tools.
我们确定了欧洲提出的肾脏风险评分(RRS)在日本抗中性粒细胞胞浆抗体(ANCA)相关性肾小球肾炎(AAGN)和高髓过氧化物酶(MPO)-ANCA 阳性患者中的有用性和预后能力;这些方面仍有待验证。
本回顾性研究纳入了 86 例日本新诊断、经活检证实的 AAGN 患者。我们计算了 RRS,并分析了这种分类与临床病理特征和预后的关系。我们还比较了 RRS 与终点(包括肾脏死亡)之间的预测值与 AAGN 患者的常规预后工具。
低、中、高危组患者分别为 33、37 和 16 例。所有患者均为 MPO-ANCA 阳性。中位随访时间为 33 个月;16 例(18.6%)患者进展为终末期肾病(ESRD)。高危组 16 例(56.3%)患者进展为 ESRD,肾脏预后明显差于其他组(低危组,P<0.001;中危组,P=0.004)。在 Cox 多变量回归分析中,RRS 是独立的不良肾脏预后因素(危险比 5.22;95%置信区间 2.20-12.40;P<0.001)。RRS 对各终点的受试者工作特征曲线与 2010 年组织学分类和日本急进性肾小球肾炎严重程度分类相当。
这是第一项报道 RRS 在预测日本 AAGN 患者肾脏结局中的有用性的研究。我们对 RRS 的预测价值与常规预后工具相当。